EC Number   |
Substrates |
Products |
Reversibility |
|---|
   2.7.1.227 | 1-phosphatidyl-1D-myo-inositol + 6-((N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-hexanoyl)-sphingosine |
- |
? |
- |
? |
| 2.7.1.227 | 1-phosphatidyl-1D-myo-inositol + C6-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ceramide |
- |
? |
- |
? |
| 2.7.1.227 | 1-phosphatidyl-1D-myo-inositol + hydroxy fatty acid-containing ceramide |
- |
hydroxy fatty acid-containing inositolphosphoylceramide |
- |
? |
| 2.7.1.227 | 1-phosphatidyl-1D-myo-inositol + N-[(2R,4E)-1-hydroxyoctadec-4-en-2-yl]octanamide |
- |
1,2-diacyl-sn-glycerol + ? |
- |
? |
| 2.7.1.227 | 1-phosphatidyl-1D-myo-inositol + N-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl]-D-erythro-sphingosine |
- |
? |
- |
? |
| 2.7.1.227 | 1-phosphatidyl-1D-myo-inositol + nonhydroxy fatty acid-containing ceramide |
- |
nonhydroxy fatty acid-containing inositolphosphoylceramide |
- |
? |
| 2.7.1.227 | L-alpha-phosphatidylinositol + C6-NBD-ceramide |
- |
? |
- |
? |
| 2.7.1.227 | more |
maximum product formation is observed at 1-phosphatidyl-1D-myo-inositol concentrations in excess of 600 microM |
? |
- |
? |
| 2.7.1.227 | more |
synthesis of ceramide derivatives built around a set of hydroxybutenyl amine cores, exploring variations in the sphingosine tail, N-acyl unit and the degree of hydroxylation. The C-3 hydroxyl group is not essential for turnover but it provides enhanced affinity. A long (C13) hydrocarbon ceramide tail is necessary for both high affinity and turnover. The N-acyl chain also contributes to affinity, analogues lacking the amide linkage function as competitive inhibitors in both enzyme and cell-based assays |
? |
- |
? |
